Malignancies - the scourge of modern times. And there is hardly a man who would say with confidence that the problem of cancer does not bother him. After all, no one is immune. That's why people read with interest about the results of research in this area.
Most recently, for example, scientists from the CMR Johns Hopkins University synthesized a unique connection, slowing tumor growth, changing microenvironment of tumors and promotes the birth of high-lymphocytes, acting directly on the cancer cells (Publication Science) magazine.
The resulting material (prolekativnaya form nonstandard amino acids of Streptomyces bacteria) labeled JHU083 code. In medicine it is "transformed" directly into the patient's body. According to the structure JHU083 similar with glutamine, but violates the metabolism of the latter, by blocking enzymes active centers.
As it is known, in the metabolism of malignant tumors glutamine plays one of the most important roles. He - a precursor of ATP, and the "fuel" for the growth of cancer cells. From this amino acid, they are divided particularly intense. And so blocking glutamine oxidation processes can help in the fight with cancer.
Glutamine, in principle, be disposed of any cells. However, the above prodrug beats just by tumor cells, both in the "most hungry." The new drug acts selectively, but its main advantage is a very definite immunotherapeutic effect, a positive effect on anti-tumor properties of T-lymphocytes.
JHU083 was tested on mice suffering from melanoma, lymphoma, and colon cancer. And during this substance inhibited growth of experimental tumors, enhancing the survival of experimental animals at different stages of disease. In this case, some of the patients could even cure the rodents. But the most interesting in the study was that the repeated administration of malignant cells have recovered the body of the mice rejected the. Scientists have suggested that the action JHU083 formed "immune memory" of animals, and therefore instantly recognize cancer cells mutant cells.
Experimentally it was found different reaction to the blockade of glutamic from the immune system and cancer cells. Using JHU083 led to depletion of tumor cells and their environment, but did T lymphocytes more active.
Scientists have also been installed improved efficiency adoptive immunotherapy (therapeutic method of enhancing the immune response) using the above-described prodrugs.
The following statement from the group stage of the research YIC Johns Hopkins University will study JHU083 combination with different types of immune therapy. Objective: To explore the possibility of certain types of tumors to overcome the "metabolic trap" created a new drug.
Want to know more about medicine? Do not forget to support our channel in service Yandex. Zen Like and subscription. It motivates us to publish more interesting materials. Also, you can quickly learn about new publications.
